HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER Compliance Director Recused From Most Duties Due To Husband's Promotion

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

The HHS general counsel determines that to prevent potential conflicts of interest, Cynthia Schnedar must no longer handle substantive issues for compliance actions and policy.

You may also be interested in...



CDER’s New Compliance Director Sklamberg Brings Experience On Compounding Issues

Howard Sklamberg, deputy associate commissioner in FDA’s Office of Regulatory Affairs, will take over as director of the Center for Drug Evaluation and Research’s Compliance Office in January; acting compliance director Ilisa Bernstein will resume her role as deputy director.

US FDA Sets FY 2021 User Fees, With Coronavirus (Somewhat) In Mind

ANDA submission rate increases, while the NDA and BLA fee drops and the biosimilar fee is unchanged.

Pink Sheet Podcast: Coronavirus Vaccines Move Into Phase III, US FDA Coronavirus Workload Changes, Rare Pediatric Priority Review Voucher Expiration

Pink Sheet reporters and editor discuss the start of Phase III coronavirus vaccine trials, FDA’s pandemic work is transitioning away from the idea stage, and the push for a permanent extension of the rare pediatric disease priority review voucher program.

Topics

UsernamePublicRestriction

Register

LL1133273

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel